Despite their promise, γδ T cells—like other cellular therapies—must overcome the profoundly immunosuppressive TME of GBM, which is characterized by Tregs, MDSCs, and TAMs that secrete inhibitory cytokines such as IL-10 and TGF-β [64]. This evidence concerns the gene TGFB1 and glioblastoma.